New Study: Options After Anti-TNF Failure In RA
This article was originally published in Scrip
Doctors participating in a new, small study reviewed a Slovenian patient registry in an attempt to answer a long-unanswered question for rheumatoid arthritis patients: After failing to respond or following a short-lived response to tumor necrosis factor (TNF) inhibitors, such as the AbbVie Inc. blockbuster Humira (adalimumab) or Amgen Inc.'s Enbrel (etanercept), is second-line treatment with another anti-TNF therapy the best option or should other mechanisms of action be considered?
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.